雲南白藥(000538.SZ):2022年白藥系列核心產品取得高速增長 雲南白藥氣霧劑收入貢獻超15億元
格隆匯7月26日丨雲南白藥(000538.SZ)近期在接待投資者調研時表示,2022年,白藥系列核心產品取得高速增長,雲南白藥氣霧劑收入貢獻超過15億元,較上年增長超過20%,雲南白藥膏、雲南白藥膠囊收入均保持良好增長。普藥產品中,感冒類獨家產品“傷風停膠囊”單品過億,風寒、風熱感冒顆粒深受廣大消費者認可;清熱解毒類蒲地藍消炎片、黃連上清片合計近3億,同品零售市場份額第一(數據來源:中康開思系統);婦科類宮血寧膠囊、天紫紅女金膠囊醫療獲機構主力推薦,婦炎康片與頭部連鎖戰略合作;兒科類小兒寶泰康顆粒單品過億,同品市場份額第一(數據來源:中康開思系統)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.